JP2016518820A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518820A5 JP2016518820A5 JP2016502169A JP2016502169A JP2016518820A5 JP 2016518820 A5 JP2016518820 A5 JP 2016518820A5 JP 2016502169 A JP2016502169 A JP 2016502169A JP 2016502169 A JP2016502169 A JP 2016502169A JP 2016518820 A5 JP2016518820 A5 JP 2016518820A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- item
- 16mer
- lna
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 13
- 108091028684 Mir-145 Proteins 0.000 claims description 10
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008263 liquid aerosol Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000008692 neointimal formation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 101150066718 FMOD gene Proteins 0.000 description 1
- 101150034559 IGF1R gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 101150103418 MEGF6 gene Proteins 0.000 description 1
- 101100338252 Mus musculus H2aw gene Proteins 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 101150048506 Rapgef2 gene Proteins 0.000 description 1
- -1 Sec1412 Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800755P | 2013-03-15 | 2013-03-15 | |
| US61/800,755 | 2013-03-15 | ||
| PCT/US2014/026538 WO2014151835A1 (en) | 2013-03-15 | 2014-03-13 | Locked nucleic acid inhibitor of mir-145 and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518820A JP2016518820A (ja) | 2016-06-30 |
| JP2016518820A5 true JP2016518820A5 (enExample) | 2017-04-06 |
| JP6410791B2 JP6410791B2 (ja) | 2018-10-24 |
Family
ID=51581048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502169A Expired - Fee Related JP6410791B2 (ja) | 2013-03-15 | 2014-03-13 | Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9752143B2 (enExample) |
| EP (1) | EP2968396B1 (enExample) |
| JP (1) | JP6410791B2 (enExample) |
| CN (1) | CN105188715B (enExample) |
| CA (1) | CA2902623A1 (enExample) |
| WO (1) | WO2014151835A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241296B2 (en) | 2005-11-17 | 2022-02-08 | Breast-Med, Inc. | Imaging fiducial markers and methods |
| WO2017184751A1 (en) * | 2016-04-20 | 2017-10-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating and preventing hypertension |
| CN110088278B (zh) * | 2016-10-31 | 2023-08-11 | e-NA生物科技公司 | 双链核酸分子及其用途 |
| JP2024504679A (ja) * | 2021-01-18 | 2024-02-01 | リジェン イノファーム インコーポレイテッド | ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物 |
| WO2025008641A2 (en) * | 2023-07-06 | 2025-01-09 | Imperial College Innovations Limited | Rna molecule |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US7803782B2 (en) | 2003-05-28 | 2010-09-28 | Roche Madison Inc. | Intravenous delivery of polynucleotides to cells in mammalian limb |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| SI20474A (sl) | 1998-05-26 | 2001-08-31 | Icn Pharmaceuticals, Inc. | Novi nukleozidi, ki imajo bicikličen sladkorni del |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| HK1048339A1 (zh) | 1999-03-18 | 2003-03-28 | 埃克西库恩公司 | 利用特异性lna引物检测基因突变 |
| DK1334109T3 (da) | 2000-10-04 | 2006-10-09 | Santaris Pharma As | Forbedret syntese af purin-blokerede nukleinsyre-analoger |
| US20050124566A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA) |
| EP2390328A1 (en) | 2001-09-28 | 2011-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| KR20050115231A (ko) | 2003-02-10 | 2005-12-07 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 포유동물 세포의 조절 |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| BRPI0508073A (pt) | 2004-02-26 | 2007-07-17 | Kardia Pty Ltd V | método e aparelho para isolar substancialmente circulação cardìaca da circulação sistêmica aparelho para perfundir o coração com um agente terapêutico, cateter de obstrução para obstruir fluxo entre um vaso principal e um ou mais vasos ramificados, método para administrar um agente terapêutico ao coração e estrutura de suporte percutaneamente administrável para manter patência do sinus coronário |
| EP2314688B1 (en) | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| WO2006107826A2 (en) | 2005-04-04 | 2006-10-12 | The Board Of Regents Of The University Of Texas System | Micro-rna's that regulate muscle cells |
| WO2006113540A2 (en) | 2005-04-14 | 2006-10-26 | Duke University | Use of ntrosylated hemoglobin |
| CN101448942B (zh) | 2005-12-12 | 2014-04-23 | 北卡罗来纳大学查珀尔希尔分校 | 调节肌细胞增殖和分化的microrna |
| KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
| US20090162240A1 (en) | 2006-04-21 | 2009-06-25 | Jfe Steel Corp. | Brake disk having high temper softening resistance |
| EP2434017A3 (en) | 2006-08-01 | 2012-09-05 | Board of Regents of the University of Texas System | Identification of a micro-RNA that activates expression of beta-myosin heavy chain |
| US8288356B2 (en) * | 2007-10-04 | 2012-10-16 | Santaris Pharma A/S | MicroRNAs |
| WO2009121031A1 (en) | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
| US8735568B2 (en) * | 2009-03-09 | 2014-05-27 | The J. David Gladstone Institutes | Methods of modulating smooth muscle cell proliferation and differentiation |
| DK2427472T3 (en) | 2009-05-05 | 2016-09-12 | Miragen Therapeutics | Lipophilic polynukleotidkonjugater |
| SG176716A1 (en) | 2009-06-08 | 2012-01-30 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
| CN102382824A (zh) | 2010-09-01 | 2012-03-21 | 中国科学院上海药物研究所 | 人miR-145反义核酸及其应用 |
| US8642751B2 (en) | 2010-12-15 | 2014-02-04 | Miragen Therapeutics | MicroRNA inhibitors comprising locked nucleotides |
| CN103814131A (zh) * | 2011-05-09 | 2014-05-21 | 格拉斯哥大学理事会 | 在肺动脉高血压的治疗中调控microrna的方法 |
| JP6208228B2 (ja) | 2012-06-21 | 2017-10-04 | ミラゲン セラピューティクス， インコーポレイテッド | ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤 |
-
2014
- 2014-03-13 US US14/777,172 patent/US9752143B2/en not_active Expired - Fee Related
- 2014-03-13 CA CA2902623A patent/CA2902623A1/en not_active Abandoned
- 2014-03-13 JP JP2016502169A patent/JP6410791B2/ja not_active Expired - Fee Related
- 2014-03-13 EP EP14768310.6A patent/EP2968396B1/en not_active Not-in-force
- 2014-03-13 CN CN201480015816.XA patent/CN105188715B/zh not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/026538 patent/WO2014151835A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| EP3128008B1 (en) | Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| JP2015525081A5 (enExample) | ||
| JP2017519766A5 (enExample) | ||
| JP2007527240A5 (enExample) | ||
| JP2017527294A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2016518820A5 (enExample) | ||
| TW201406774A (zh) | 微ｒｎａ之ｍｉｒ－１５家族之抑制劑 | |
| JP7318166B2 (ja) | マイクロｒｎａ２２の阻害剤 | |
| EP2948551B1 (en) | Composition comprising an encapsulated antagomir | |
| JP2009537153A5 (enExample) | ||
| JP2019524151A5 (enExample) | ||
| JP2011515357A5 (enExample) | ||
| JP6410791B2 (ja) | Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用 | |
| TW202342747A (zh) | 具有高穩定性和基因沉默活性的小干擾rna分子的修飾模式 | |
| KR20150064065A (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna 를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
| KR102110103B1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP2024529930A (ja) | 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子 | |
| WO2023097232A1 (en) | Methods for treating glioblastoma by targeting oncomirs | |
| US20230265426A1 (en) | Combinatorial inhibition of mirnas for treatment of heart failure | |
| JP7692829B2 (ja) | Ｍｕｒｆ１を標的とする核酸医薬 | |
| US20240327830A1 (en) | Dise-inducing srna-polyplexes and srna-lipopolyplexes and methods of using the same to treat cancer | |
| JP2024057599A (ja) | マイクロｒｎａ２２の阻害剤 |